A colorectal cancer drug under development by Bayer HealthCare modestly improved overall survival in some of the sickest patients in a late-stage trial, partner Onyx Pharmaceuticals Inc. said Tuesday, and Bayer will seek Food and Drug Administration approval of the drug this year.
The median overall survival of patients on experimental regorafenib was 6.4 months. That compares to five months for patients who were given a placebo.
Onyx called the finding, released at the American Society of Clinical Oncology’s gastrointestinal cancer meeting in San Francisco, statistically significant. But critics appeared less than wowed by the small improvement.